Latest Commercialization News

Anson Resources has inked a key lithium supply deal with LG Energy Solution and made significant progress on its Green River Lithium Project in Utah, backed by a $5 million capital raise.

EMVision Medical Devices has successfully closed an oversubscribed Share Purchase Plan, raising $2 million and bringing total recent capital to $14 million. This funding positions the company to advance pivotal clinical trials and regulatory milestones for its innovative neurodiagnostic devices.

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.

FirstWave Cloud Technology reports a cash-flow positive quarter with a $2.85 million capital raise and advances its AI-powered compliance product, targeting a commercial release by November.

Vulcan Steel reported a sharp profit decline in FY25 amid tough market conditions but strengthened its balance sheet and expanded into roofing with a major acquisition. Leadership changes set the stage for renewed growth.

Pure Hydrogen Corporation reported strong commercial momentum in the September 2025 quarter, securing multiple hydrogen vehicle orders across Australia and the US, expanding international distribution, and raising fresh capital to fuel growth.

Emperor Energy has secured a significant resource upgrade for its Judith Gas Field and raised $3.7 million to progress the Judith-2 appraisal well, targeting commercial gas supply in a tightening East Coast market.

HITIQ Ltd has secured a landmark order for its PROTEQT™ mouthguards at the Winter Olympics and launched in the UK consumer market, while advancing global validation and raising over A$2 million in capital.

International Graphite Limited has made significant strides in its global graphite strategy, signing a German joint venture and securing $3 million in US institutional funding to support its expanding mine-to-market operations.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

The Treasurer has expressed preliminary concerns that Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma could harm Australia’s economy, citing plans to close a key Adelaide manufacturing site. Mayne Pharma disputes these claims and urges a resolution before the scheme deadline.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.